Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Hurst

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Frontiers in Immunology|September 16, 2022
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruptionMatthew Pace, Ane Ogbe, Jacob Hurst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic MelanomaMark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.
Nature Communications|October 10, 2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruptionJacob Hurst, Matthias Hoffmann, Matthew Pace, et al.
Plos Pathogens|June 16, 2015
Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV InfectionEmily Adland, Paolo Paioni, Christina Thobakgale, et al.
Science Translational Medicine|September 30, 2016
Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infectionMaximilian Muenchhoff, Emily Adland, Owen Karimanzira, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Frontiers in Immunology|September 16, 2022
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruptionMatthew Pace, Ane Ogbe, Jacob Hurst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic MelanomaMark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.
Nature Communications|October 10, 2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruptionJacob Hurst, Matthias Hoffmann, Matthew Pace, et al.
Plos Pathogens|June 16, 2015
Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV InfectionEmily Adland, Paolo Paioni, Christina Thobakgale, et al.
Science Translational Medicine|September 30, 2016
Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infectionMaximilian Muenchhoff, Emily Adland, Owen Karimanzira, et al.
Pageof 3